NCT00000317View on ClinicalTrials.gov

Early Phase II Trials for Cocaine Medication Development - 1

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 31, 1996

Primary Completion Date

July 31, 1999

Study Completion Date

July 31, 1999

Conditions
Cocaine-Related DisordersSubstance-Related Disorders
Interventions
DRUG

Risperidone

Risperidone (4mg/day)

DRUG

Placebo

Placebo

BEHAVIORAL

Relapse prevention counseling

Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.

Trial Locations (1)

10032

NYS Psychiatric Institute, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Research Foundation for Mental Hygiene, Inc.

OTHER

lead

New York State Psychiatric Institute

OTHER

NCT00000317 - Early Phase II Trials for Cocaine Medication Development - 1 | Biotech Hunter | Biotech Hunter